Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

Conditions

• Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
• Diabetic Foot Ulcers (DFUs)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Miro3D Wound Matrix — DEVICE
  Miro3D is a sterile, acellular, three-dimensional biologic wound matrix derived from porcine liver via perfusion decellularization and drying. It is trimmed to fit the wound and rehydrated with sterile saline or Lactated Ringer's solution before application. It provides a porous scaffold to support granulation and healing in chronic or post-surgical wounds.
• Standard of Care (SOC) — OTHER
  SOC includes standard wound care practices such as wound cleansing, debridement, infection management (if applicable), use of protective dressings (e.g., Aquacel or foam covered with Adaptic), and offloading devices (e.g., Foot Defender boot) to relieve pressure on the wound.

Study Details

This study is a prospective, randomized controlled trial designed to evaluate the effectiveness of Miro3D Wound Matrix plus Standard of Care (SOC) compared to SOC alone in treating Wagner Grade 1 diabetic foot ulcers (DFUs) and wound dehiscence in an outpatient setting. The trial is sponsored by Reprise Biomedical, Inc. and aims to explore whether the addition of Miro3D-a three-dimensional, acellular porcine-derived wound matrix-enhances wound healing outcomes compared to SOC alone. Purpose of the Study: The primary purpose of the study is to determine whether applying Miro3D in combination with SOC leads to improved healing of diabetic foot ulcers compared to SOC alone. Specifically, the study seeks to assess early wound healing progress at four weeks (as measured by percent area reduction and granulation tissue formation) as a predictor of complete healing by twelve weeks. Key Question the Study Seeks to Answer: Does the addition of Miro3D to standard wound care improve the healing rate and overall wound outcomes for patients with Wagner Grade 1 diabetic foot ulcers or dehisced wounds compared to standard care alone? Study Design Overview: Subjects who meet inclusion/exclusion criteria will be randomized into one of two groups: 1. Miro3D + SOC arm - receiving Miro3D weekly for 4 weeks, then biweekly if needed, for up to 12 weeks. 2. SOC alone (control) arm - receiving SOC without Miro3D. If the wound remains unhealed at 12 weeks in the SOC alone arm, participants may "crossover" to receive Miro3D treatment under the same schedule for an additional 12 weeks. Primary Endpoint: 1\. Percent Area Reduction (PAR) and granulation tissue formation at 4 weeks, serving as predictors for wound healing at 12 weeks. Secondary Endpoints: 1. Quality of Life (QOL) improvements, including pain, mobility, and emotional well-being, assessed using a validated Wound/Ulcer-QOL tool. 2. Pain levels using a Visual Analog Scale (VAS) at each visit. Population: Approximately 30 adult subjects (15 per arm) with Wagner Grade 1 diabetic foot ulcers or dehisced wounds will be enrolled. Subjects must have adequate blood flow, demonstrate wound size criteria, and commit to offloading and follow-up care. Follow-Up: Subjects will be followed weekly through the 12-week study period. Healed subjects will undergo confirmation visits at 2 and 4 weeks post-closure. Subjects in the crossover arm will be followed for an additional 12 weeks if their wound was unhealed at the primary endpoint. Statistical Considerations: Data will be summarized using descriptive statistics, including wound measurements, infection status, and healing rates. Comparative analysis will be conducted between treatment groups and schedules (weekly vs. biweekly Miro3D application). Adverse events (AEs), serious adverse events (SAEs), and device-related events will also be documented. This study aims to generate clinical evidence supporting the use of Miro3D as a beneficial adjunct to standard wound care in promoting early and complete healing of diabetic foot ulcers.

Key Dates

Start date

Nov 1, 2024

Status verified

Dec 2025

Primary completion

Jul 31, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

30 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Experimental: Miro3D Wound Matrix plus Standard of Care (SOC)
  Subjects randomized to this arm receive Miro3D Wound Matrix in combination with standard of care wound treatment. * Miro3D is applied once every 7 days for the first 4 weeks. * If the wound is not healed after 4 weeks, Miro3D is applied biweekly (every 14 days) through week 12 or until healing. * All subjects in this arm are assessed weekly for healing progress, wound measurements, granulation, pain (VAS), and QOL.
• Active Comparator: Standard of Care (SOC) Alone
  Subjects in this arm receive standard wound care without Miro3D, including wound cleaning, debridement, offloading, and appropriate dressings. * Healing progress is evaluated weekly over the 12-week treatment period. * Subjects whose wounds remain unhealed at week 12 may elect to crossover to Miro3D treatment, following the same protocol used in Arm 1.

Primary Outcome Measure

Percent Area Reduction (PAR) and Granulation Tissue Formation at 4 Weeks [ Time Frame: 4 weeks post-randomization ]

Central Contacts

• Maria Swartz
  954-721-4806
  [email protected]

Locations (3)

Find similar trials in Coconut Creek, FL

Related Studies

• Correlating Multispectral Near-Infrared Imaging to Standard Vascular Diagnostics
  Recruiting · MIMOSA Diagnostics Inc. · Lake Success, New York
• Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
  Recruiting · Reprise Biomedical, Inc. · Coconut Creek, Florida
• Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
  Recruiting · Reprise Biomedical, Inc. · Phoenix, Arizona
• A Real-World Registry of Chronic Wounds and Ulcers
  Recruiting · U.S. Wound Registry · The Woodlands, Texas